Abstract
Hematogenous dissemination of single cancer cells is a common phenomenon in patients with solid tumors. These cells may experience different fates: most will die during the process; some will grow into metastasis and some will persist in secondary homing sites for many years in a state referred to as dormancy. The mechanisms of this state are still not clear; single cancer cells can survive either by completely withdrawing from the cell cycle or by continuing to proliferate at a slow rate that is counterbalanced by cell death. Another hypothesis assumes that at least some of dormant tumor cells feature stem cell-like characteristics that may contribute to their extremely long half-lives and enhance chemotherapy resistance. Breast cancer is particularly known for prolonged periods of clinical freedom of disease (sometimes up to 20–30 years), followed by a distant relapse. In this chapter, we explore the relationship between the clinical phenomenon of tumor dormancy and the disseminated tumor cells and discuss the potential implications for treatment.
| Originalsprache | Englisch |
|---|---|
| Titel | Advances in Experimental Medicine and Biology |
| Seitenumfang | 9 |
| Herausgeber (Verlag) | Springer |
| Erscheinungsdatum | 2020 |
| Seiten | 35-43 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 2020 |
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
Strategische Forschungsbereiche und Zentren
- Profilbereich: Lübeck Integrated Oncology Network (LION)
- Zentren: Universitäres Cancer Center Schleswig-Holstein (UCCSH)
Fingerprint
Untersuchen Sie die Forschungsthemen von „Disseminated Tumor Cells and Dormancy in Breast Cancer Progression“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver